Drug
Tenapanor clinical trials
Also written AZD1722, RDX5791 and IBSRELA.
Keep track of what changes. Save the tenapanor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
36 studies that test it; most in 2013 (6)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 6 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 32 · Other 4
Ardelyx (25) · Kyowa Kirin Co., Ltd. (7) · Massachusetts General Hospital (1) · University of Texas Southwestern Medical Center (1) · Kyle Staller, MD, MPH (1) · Cedar Valley Digestive Health Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tenapanor is read from its arms, and is right about nine times in ten.
Testing it · 36
- Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-CEnrolling by invitationPhase 3ArdelyxNCT05905926Written as Tenapanor
- A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in AdultsRecruitingPhase 3ArdelyxNCT07382167Written as Tenapanor 5 mg BID
- Tenapanor in Synucleinopathy-Related ConstipationRecruitingPhase 2Cedar Valley Digestive Health CenterNCT06460038Written as Tenapanor
- A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.CompletedPhase 4University of Texas Southwestern Medical CenterNCT06481150Written as Tenapanor
- Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsCompletedPhase 3ArdelyxNCT05643534Written as Tenapanor 50 MG
- Assessing Tenapanor as a Treatment of CF-related Constipation.Active, not recruitingPhase 3Massachusetts General HospitalNCT06810167Written as Tenapanor
- 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsCompletedPhase 2ArdelyxNCT06553547Written as Tenapanor
- Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With ConstipationCompletedPhase 4Kyle Staller, MD, MPHNCT05995899Written as Tenapanor
- An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating FemalesCompletedPhase 1ArdelyxNCT06203444Written as Tenapanor
- Dose-finding Study of KHK7791 in Hyperphosphatemia PatientsCompletedPhase 2Kyowa Kirin Co., Ltd.NCT03864458Written as KHK7791
- A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HDCompletedPhase 2Kyowa Kirin Co., Ltd.NCT03831607Written as KHK7791
- Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia PatientsCompletedPhase 2Kyowa Kirin Co., Ltd.NCT03864445Written as KHK7791
- Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisCompletedPhase 3Kyowa Kirin Co., Ltd.NCT04771780Written as KHK7791
- A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisCompletedPhase 3ArdelyxNCT03427125Written as Tenapanor
- A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HPCompletedPhase 4ArdelyxNCT03988920Written as Tenapanor
- Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of HyperphosphatemiaCompletedPhase 4ArdelyxNCT04549597Written as Tenapanor
- Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder TherapyCompletedPhase 2/3ArdelyxNCT03824587Written as Tenapanor
- Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal DialysisCompletedPhase 3Kyowa Kirin Co., Ltd.NCT04766385Written as KHK7791
- Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisCompletedPhase 3Kyowa Kirin Co., Ltd.NCT04766398Written as KHK7791
- Clinical Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisCompletedPhase 3Kyowa Kirin Co., Ltd.NCT04767581Written as KHK7791
See all 36 studies that test tenapanor →
Given in every arm · 1 — tenapanor is usual care beside what is tested
Codes
What other systems call tenapanor · ClinicalTrials.gg INT000263
- MeSH (NLM) C000599417tenapanorConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) WYD79216A6TENAPANORConfirmed FDA, NLM, Wikidata
- RxNorm 2199674One source FDA
- Wikidata Q17122912tenapanorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152555TenapanorOne source FDA
- DrugBank DB11761One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599417 | tenapanor | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | WYD79216A6 | TENAPANOR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2199674 | — | One source FDA |
| Wikidata | Q17122912 | tenapanor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152555 | Tenapanor | One source FDA |
| DrugBank | DB11761 | — | One source Wikidata |
Also registered as tenapanor hydrochloride (UNII 50605O2ZNS · RxNorm 2199673).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.